SEC Form 4 · accession 0001225208-18-015527
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
G Leonard Baker Jr.
Director
Period of report
Nov 9, 2018
Accepted (ET)
Nov 14, 2018 · 5:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 9, 2018 | P | 17,428 | $13.00 | A | 894,266 | D | |
| Common StockF2 | Nov 12, 2018 | P | 31,677 | $12.9434 | A | 925,943 | D | |
| Common StockF3 | Nov 13, 2018 | P | 10,895 | $12.868 | A | 936,838 | D | |
| Common StockF1,F4 | Nov 9, 2018 | P | 40,666 | $13.00 | A | 2,875,459 | I | By Ltd Partnership |
| Common StockF2,F4 | Nov 12, 2018 | P | 73,914 | $12.9434 | A | 2,949,373 | I | By Ltd Partnership |
| Common StockF3,F4 | Nov 13, 2018 | P | 25,420 | $12.868 | A | 2,974,793 | I | By Ltd Partnership |
| Common StockF5 | holding | — | — | — | 955,055 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.99 to $13.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.72 to $13.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.75 to $13.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F4Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
- F5Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.